Anemia Drugs May Raise Death Risk in Cancer Patients

Related Encyclopedia • Adenocarcinoma of the Lung and Brain Metastases • Aneurysms • Angina Pectoris • Angiogram More... Related Healthscout Videos Disaster Heart Attacks Teaching Old Docs New Tricks Optimistic Healing What's Your Stroke IQ? More... Related Animations • Angioplasty • Breast Self-Exam Video • Colon Cancer • Coronary Bypass Surgery More... Related Drug Information • Accupril • Altace • Avapro • Cartia XT More... Related News Articles • Drugs Provide Same Benefit as Angioplasty for Diabetics, at Lower Cost • Study: Migraine Raises Risk of Stroke • Low Vitamin D Tied to Estrogen Decline • Hormone Therapy & Breast Cancer More...

Page:  << Prev | 1 | 2 | 3

The findings "show that erythropoiesis-stimulating agents increase mortality in all patients with cancer, and a similar increase might exist in patients on chemotherapy," the authors wrote. "In clinical practice, the increased risks of death and thromboembolic events should be balanced against the benefits of treatment with erythropoiesis-stimulating agents, taking into account each patient's clinical circumstances and preferences. More data are needed for the effect of these drugs on quality of life and tumor progression, and meta-analyses similar to this one will address these questions," they added.

Dr. Charles Bennett, the A.C. Beuhler professor of geriatric medicine at the Feinberg School of Medicine at Northwestern University, helped conduct a study, published in the Journal of the American Medical Association early last year, that also found similar risks for the use of ESAs by cancer patients. He believes the new data support those findings.

"The message is clear: There is a safety concern that's real and significant," Bennett said.

Text Continues Below

---

In addition, Bennett believes that quality-of-life issues and the need for a reduction in blood transfusions for cancer patients are overstated. "The [appropriate] use of these drugs in the United States is for palliative care in cancer patients and I support that," he said.

More information

For more information on ESAs, visit the U.S. Food and Drug Administration.

Page:  << Prev | 1 | 2 | 3